secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0000950170-22-012595
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences estimates $307M cash, cash equivalents and marketable securities as of June 30, 2022
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities balance of approximately $307 million as of June 30, 2022.
- Estimate is unaudited and subject to quarter-end closing adjustments.
- No other financial results for Q2 2022 provided; comprehensive statement not yet available.
- Company emphasizes this is a preliminary estimate and not a complete financial report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022012595/0000950170-22-012595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017022012595/kzr-20220711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer